RxDoctor Payments Data

John Dallas, MD

Pulmonary Disease · Austin, TXNPI 1972687127

Payments from drug & device makers

$80,585in general payments, 2019–2025

Across 208 payments — averaging $387.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$79K
  • United Therapeutics Corporation$488
  • Sunovion Pharmaceuticals Inc.$174
  • Edwards Lifesciences$147
  • Merck$126
  • Bayer$125
  • plus $35 from 1 others

What the payments were for

  • Consulting fees$3,3604%
  • Speaking & faculty fees$70,59088%
  • Travel & lodging$1,2982%
  • Food & beverage$5,3377%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,585 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$54,878
Medicare patients
168
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan352$4,473,557
UptraviSelexipag185$4,030,525
WinrevairSotatercept-Csrk102$2,022,465
AdempasRiociguat83$1,094,863
Tyvaso DpiTreprostinil29$647,942
Orenitram ErTreprostinil Diolamine23$589,703
OfevNintedanib Esylate35$452,299
Ambrisentan56$277,624
Tadalafil243$196,756
LetairisAmbrisentan12$158,626
AdcircaTadalafil22$85,357
EliquisApixaban20$18,221
Sildenafil Citrate21$5,400
Breo ElliptaFluticasone/Vilanterol12$4,476
Potassium Chloride82$2,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$79,490$8,504,082537 claims
MerckWinrevair$126$2,022,465102 claims
BayerAdempas$125$1,094,86383 claims
GileadLetairis$35$158,62612 claims
United Therapeutics CorporationAdcirca$488$85,35722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →